Menu
Menu
274693-27-5
Blood Related
C23H28F2N6O4S
522.6 g/mol
Amorphous
Commercial
Ready
Ready
Ticagrelor is a P2Y12 platelet inhibitor used in patients with a history of myocardial infarction or with acute coronary syndrome (ACS) to prevent future myocardial infarction, stroke, and cardiovascular death. It is also used to prevent blood clots from forming in people who have received coronary stents to treat ACS. Ticagrelor is used to decrease the risk of a first-time heart attack or stroke in people at risk with coronary artery. It is also used to decrease the risk of another stroke, of higher severity, in people who have already had a mild to moderate stroke or a transient ischemic attack. Ticagrelor is in a class of medications called antiplatelet which prevents blood cells from collecting and forming clots that may cause a heart attack or stroke. This drug can be used as monotherapy or in combination with other medicines. Ticagrelor is administered through oral route by way of film-coated tablets or via nasogastric tube ensuring the tablet is crushed and mixed in water.
Ticagrelor is a P2Y12 receptor antagonist. The P2Y12 receptor couples with Gαi2 and other Gi proteins which inhibit adenylyl cyclase. Gi mediated signaling also activates PI3K, Akt, Rap1b, and potassium channels. The downstream effects of these activities mediate hemostasis and lead to platelet aggregation. Antagonism of the P2Y12 receptor reduces development of occlusive thromboses, which can reduce the risk of myocardial infarction and ischemic stroke. The reversible binding allows Ticagrelor to redistribute to new platelets as they are formed.
Ornet Pharmaceuticals, based out of Gujarat, India, is a leading manufacturer and global supplier of Ticagrelor API. Driven by technically sound, research-oriented leaders, each with over 2 decades of hands-on experience, Ornet develops and manufactures a wide array of complex APIs catering to multiple categories in its product portfolio, such as anti-diabetics, blood related, hormones, etc. Ornet’s Ticagrelor API is the result of the “Quality over Quantity” approach taken by the organization for all R&D and manufacturing practices. This approach, along with the strategically located manufacturing facility in Gujarat, allows for Ornet to be a primary source, both domestically and globally, for all API needs.
Products protected by valid patents are not offered for commercial sale in countries where the sale of such products constitutes patent infringement but are offered solely for uses reasonably related to the development and submission of information under a law regulating the manufacture, use or sale of drugs. It is within the buyer’s responsibility and liability to check the patent situation of the product in the imported market(s).
